(Q33368219)

English

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

Branimir Ivan Sikic

9

object named as

Branimir I Sikic

1 reference

Europe PubMed Central

26 July 2017

Ranjana H. Advani

1

object named as

Ranjana Advani

1 reference

Europe PubMed Central

26 July 2017

author name string

Bert L Lum

2

1 reference

Europe PubMed Central

26 July 2017

George A Fisher

3

1 reference

Europe PubMed Central

26 July 2017

Joanne Halsey

4

1 reference

Europe PubMed Central

26 July 2017

Richard S Geary

5

1 reference

Europe PubMed Central

26 July 2017

Jon T Holmlund

6

1 reference

Europe PubMed Central

26 July 2017

T Jesse Kwoh

7

1 reference

Europe PubMed Central

26 July 2017

F Andrew Dorr

8

1 reference

Europe PubMed Central

26 July 2017

publication date

1 October 2005

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

23

1 reference

Europe PubMed Central

26 July 2017

5

1 reference

Europe PubMed Central

26 July 2017

467-477

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-005-2906-0

0 references

Inhibition of coagulation by a phosphorothioate oligonucleotide.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2906-0

21 January 2018

Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in antisense oligonucleotide therapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of phosphorothioate oligonucleotides in human plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of protein kinase C and role in cancer biology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The potential of protein kinase C as a target for anticancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-2906-0

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33368219&oldid=1868623257"